#1 Clinical Trials Search in Europe

Rifampicin

Rifampicin, a powerful antibiotic, is the subject of numerous clinical trials aimed at improving treatment for tuberculosis and other bacterial infections. These studies explore various aspects of rifampicin use, including different dosages, administration methods, and combinations with other drugs. The research seeks to enhance the drug’s effectiveness, optimize dosing regimens, and investigate its potential in treating various conditions beyond tuberculosis.

Table of Contents

What is Rifampicin?

Rifampicin, also known as rifampin, is an important antibiotic used to treat various bacterial infections[1]. It belongs to a class of drugs called rifamycins and works by stopping the growth of bacteria[2]. Rifampicin is available in different forms, including tablets, capsules, and intravenous (IV) preparations[3].

Uses of Rifampicin

Rifampicin is used to treat several types of infections, including:

  • Tuberculosis (TB): Rifampicin is a key component in the treatment of TB, including pulmonary TB (affecting the lungs) and TB meningitis (affecting the brain)[4][3].
  • Staphylococcal infections: These include bone and joint infections caused by Staphylococcus bacteria[1][5].
  • Prosthetic joint infections: Infections that occur in artificial joints[1].
  • Multidrug-resistant bacterial infections: Rifampicin is sometimes used to treat infections caused by bacteria that are resistant to other antibiotics[6].

Dosage and Administration

The dosage of rifampicin can vary depending on the type of infection being treated and the patient’s age and weight. Some common dosages include:

  • For adults with TB: 10 mg/kg per day (usually 600 mg to 1,200 mg) taken orally once daily[7].
  • For children with TB: Dosage is usually weight-based and can range from 10-20 mg/kg per day[8].
  • For bone and joint infections: Dosages can range from 10 mg/kg/day to 20 mg/kg/day, depending on the severity of the infection[5].

Rifampicin is often given in combination with other antibiotics to prevent the development of drug resistance[6]. The duration of treatment can vary from a few weeks to several months, depending on the type and severity of the infection[5].

Side Effects and Safety

Like all medications, rifampicin can cause side effects. Common side effects may include:

  • Gastrointestinal issues such as nausea, vomiting, and diarrhea
  • Liver problems, which may cause yellowing of the skin or eyes (jaundice)
  • Skin rashes or itching
  • Changes in urine, sweat, or tear color (usually harmless but can be alarming)

More serious side effects, though rare, can include severe liver damage or allergic reactions[5]. It’s important to report any unusual symptoms to your healthcare provider promptly.

Drug Interactions

Rifampicin can interact with many other medications, potentially affecting their effectiveness or increasing the risk of side effects. Some important interactions include:

  • HIV medications: Rifampicin can reduce the effectiveness of some antiretroviral drugs used to treat HIV[8].
  • Blood thinners: Rifampicin may decrease the effectiveness of certain blood-thinning medications[9].
  • Oral contraceptives: Rifampicin can make birth control pills less effective[1].

Always inform your healthcare provider about all medications, supplements, and herbal products you are taking before starting rifampicin.

Ongoing Research

Researchers are continuously studying rifampicin to improve its use and effectiveness. Some areas of ongoing research include:

  • Higher doses of rifampicin for TB treatment: Studies are exploring whether higher doses of rifampicin could lead to shorter treatment durations or better outcomes[2].
  • Combination therapies: Researchers are investigating the effectiveness of rifampicin in combination with other antibiotics for various infections[6].
  • Use in special populations: Studies are examining the use of rifampicin in specific groups, such as children with HIV and TB co-infection[8].

These ongoing studies aim to optimize the use of rifampicin and improve treatment outcomes for patients with various bacterial infections.

Aspect Details
Main Conditions Studied Tuberculosis (pulmonary and meningeal), leprosy, staphylococcal bone and joint infections
Dosage Ranges 10 mg/kg to 55 mg/kg, with some trials exploring doses up to 900 mg
Administration Routes Oral (tablets/capsules) and intravenous
Combination Therapies Often combined with isoniazid, pyrazinamide, ethambutol, and other antibiotics
Key Outcome Measures Pharmacokinetics, early bactericidal activity, treatment success rates, mortality reduction
Safety Monitoring Liver function, gastrointestinal effects, cardiac effects (QT interval), adverse events
Special Populations Children, HIV/TB co-infected patients
Novel Approaches High-dose rifampicin, whole blood bactericidal activity, bioequivalence studies of fixed-dose combinations

FAQ

  • What is rifampicin used for in clinical trials? Rifampicin is primarily used in clinical trials for treating tuberculosis (TB), including pulmonary TB and TB meningitis. It's also being studied for use in other bacterial infections, such as staphylococcal bone and joint infections.
  • Why are researchers exploring higher doses of rifampicin? Higher doses of rifampicin are being studied to potentially improve treatment outcomes, reduce treatment duration, and combat drug-resistant strains of bacteria. Some trials are comparing standard doses to higher doses to determine if increased efficacy can be achieved without compromising safety.
  • How is rifampicin administered in these trials? Rifampicin is administered in various ways depending on the study. Some trials use oral tablets or capsules, while others explore intravenous administration. The drug is often given in combination with other antibiotics as part of a treatment regimen.
  • What are some potential side effects of rifampicin being monitored in these trials? Researchers are monitoring for various side effects, including liver function abnormalities, gastrointestinal issues (like nausea and vomiting), changes in heart rhythm (QT interval), and skin reactions. The trials also assess the overall safety and tolerability of different rifampicin doses.
  • How do clinical trials measure the effectiveness of rifampicin? The effectiveness of rifampicin is measured through various methods, including pharmacokinetic studies (measuring drug concentrations in blood and cerebrospinal fluid), early bactericidal activity (reduction in bacterial counts), and clinical outcomes such as treatment success rates and mortality reduction.

Ongoing Clinical Trials on Rifampicin

  • Study of Switching from Intravenous to Oral Antibiotics in Patients with Infective Endocarditis Using a Drug Combination

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

  • Study comparing dalbavancin to standard antibiotic treatment for patients with periprosthetic joint infection

    Recruiting

    1 1 1 1
    Investigated drugs:
    Denmark

  • Study evaluating blood biomarkers for diagnosis and monitoring treatment in patients with pulmonary tuberculosis using isoniazid, rifampicin, pyrazinamide, and ethambutol combination

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on High-Dose Rifampicin Safety for Adults with Complex Tuberculosis Using Isoniazid, Pyrazinamide, and Ethambutol Combination

    Recruiting

    1 1 1
    Investigated drugs:
    The Netherlands Spain

  • Study on Clindamycin and Rifampicin for Treating Infections in Patients with Obesity, Fracture-Related Infections, Hidradenitis Suppurativa, or Prosthetic Joint Infections

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

  • Study on Continuous vs. Intermittent Infusion of Ampicillin and Ceftriaxone for Patients with Enterococcus faecalis Infective Endocarditis

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on the Effects of Tedizolid and Linezolid for Patients with Suspected Lung Tuberculosis

    Recruiting

    1 1 1
    Investigated drugs:
    France

  • Study Comparing Dalbavancin to Standard Antibiotics for Patients with Staphylococcus aureus Bloodstream Infections

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study Comparing Clarithromycin and Azithromycin for Treating Mycobacterium Avium Complex Lung Infections in Adults

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effectiveness of Moxifloxacin and Drug Combination for Treating Bone Implant Infections in Patients with Long Bone Fractures

    Recruiting

    1 1 1 1
    Investigated drugs:
    Spain

Glossary

  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion. PK studies help determine the best dosing regimens for medications.
  • Early Bactericidal Activity (EBA): A measure of how quickly and effectively an antibiotic kills bacteria in the early stages of treatment. It's often used in TB studies to assess drug efficacy.
  • Fixed-Dose Combination (FDC): A pill or capsule that contains two or more drugs in fixed doses. FDCs are often used in TB treatment to simplify medication regimens and improve adherence.
  • Bioavailability: The proportion of a drug that enters the circulation when introduced into the body and is able to have an active effect.
  • Area Under the Curve (AUC): A measure of the total exposure to a drug over time, used in pharmacokinetic studies to assess drug absorption and effectiveness.
  • Maximum Concentration (Cmax): The peak concentration of a drug in the blood after administration, used to evaluate drug absorption and exposure.
  • Whole Blood Bactericidal Activity (WBA): A laboratory test that measures the ability of a patient's blood, containing the administered drug, to kill bacteria. It's used to assess the effectiveness of antibiotics.
  • Post-Exposure Prophylaxis (PEP): The use of medication to prevent infection after potential exposure to a pathogen, such as in the case of leprosy contacts receiving rifampicin.

References

  1. https://clinicaltrials.eu/trial/study-comparing-rifabutin-and-rifampicin-for-adults-with-staphylococcal-prosthetic-joint-infection-using-dair-strategy/
  2. https://clinicaltrials.gov/study/NCT01392911
  3. https://clinicaltrials.gov/study/NCT01802502
  4. https://clinicaltrials.gov/study/NCT02387242
  5. https://clinicaltrials.gov/study/NCT02599493
  6. https://clinicaltrials.gov/study/NCT01577862
  7. https://clinicaltrials.gov/study/NCT02953847
  8. https://clinicaltrials.gov/study/NCT05069688
  9. https://clinicaltrials.gov/study/NCT01932268